HMTXF.US Hemostemix Inc

Healthcare Biotechnology USA Stocks
0.0350 USD
Close of Nov 15, 2026
0.0350 0.0762
Market cap
USD 7.40M
P/E
-
P/B
39.23x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HMTXF.US undervalued?

Graham number

The Graham number of Hemostemix Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hemostemix Inc fundamental analysis

No fundamental analysis for Hemostemix Inc yet.

Hemostemix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hemostemix Inc

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain…

Full company profile